LivaNova PLC (NASDAQ:LIVN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of LivaNova PLC (NASDAQ:LIVN) have been assigned an average rating of “Moderate Buy” from the ten analysts that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $74.1111.

Several equities analysts recently commented on LIVN shares. The Goldman Sachs Group reiterated a “neutral” rating and set a $66.00 price target on shares of LivaNova in a report on Friday, January 9th. Stifel Nicolaus set a $80.00 target price on LivaNova in a research note on Wednesday. Mizuho raised their price target on LivaNova from $70.00 to $72.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 17th. KeyCorp started coverage on LivaNova in a report on Friday, December 19th. They set an “overweight” rating and a $81.00 price objective for the company. Finally, Needham & Company LLC increased their target price on LivaNova from $64.00 to $81.00 and gave the stock a “buy” rating in a research note on Wednesday.

LivaNova Price Performance

NASDAQ:LIVN opened at $70.29 on Thursday. The firm has a market capitalization of $3.84 billion, a price-to-earnings ratio of -17.57 and a beta of 0.97. LivaNova has a 1 year low of $32.48 and a 1 year high of $70.78. The business has a 50 day simple moving average of $64.41 and a 200-day simple moving average of $58.81. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.33 and a quick ratio of 1.12.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings results on Wednesday, February 25th. The company reported $0.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.80 by $0.06. LivaNova had a positive return on equity of 15.98% and a negative net margin of 16.12%.The company had revenue of $360.86 million during the quarter, compared to the consensus estimate of $354.31 million. During the same period last year, the company earned $0.81 earnings per share. LivaNova’s revenue was up 12.2% on a year-over-year basis. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. Equities analysts forecast that LivaNova will post 2.85 EPS for the current year.

LivaNova News Roundup

Here are the key news stories impacting LivaNova this week:

• Positive Sentiment: Q4 results beat on both revenue and adjusted EPS; revenue was ~$360.9M (up ~12% y/y) and adjusted EPS topped consensus — management issued FY‑2026 adjusted EPS guidance of $4.15–$4.25, above Street estimates, which is the main near-term catalyst. Read More.
• Positive Sentiment: Analyst upgrade/price-target lift: Needham raised its price target to $81 and reiterated a Buy rating, reinforcing bullish sentiment following the results and guidance. Read More.
• Positive Sentiment: Short interest declined materially in February (down ~16.6% to ~2.03M shares), lowering potential downward pressure from short squeezes and signaling reduced bearish positioning into the earnings update.
• Neutral Sentiment: Management materials and the full earnings call transcript are available for deeper read-throughs (useful for assessing margin drivers and product/service momentum). Read More. · Read More.
• Neutral Sentiment: Market commentary is starting to assess longer-term drivers such as reimbursement gains and a new data partnership (Orrum) that could reshape cardiac-care positioning; these are potential catalysts but currently speculative. Read More. · Read More.
• Negative Sentiment: GAAP metrics and margins still show weaknesses: reported GAAP diluted EPS was lower than adjusted EPS and the company reported a negative net margin (~‑16%), suggesting non‑operating items or charges and that underlying profitability still needs improvement. Investors should monitor whether adjusted guidance is supported by sustained operating margin improvement. Read More.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Artisan Partners Limited Partnership lifted its position in shares of LivaNova by 94.5% during the third quarter. Artisan Partners Limited Partnership now owns 2,427,045 shares of the company’s stock valued at $127,129,000 after buying an additional 1,179,436 shares during the last quarter. Wellington Management Group LLP increased its position in LivaNova by 83.5% during the 3rd quarter. Wellington Management Group LLP now owns 2,345,516 shares of the company’s stock valued at $122,858,000 after buying an additional 1,067,349 shares in the last quarter. Invesco Ltd. raised its stake in LivaNova by 714.7% in the second quarter. Invesco Ltd. now owns 1,028,713 shares of the company’s stock valued at $46,313,000 after buying an additional 902,447 shares during the last quarter. Scopia Capital Management LP purchased a new stake in LivaNova in the second quarter valued at about $36,657,000. Finally, Millennium Management LLC boosted its holdings in LivaNova by 22.4% in the third quarter. Millennium Management LLC now owns 2,969,814 shares of the company’s stock worth $155,559,000 after acquiring an additional 544,033 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.